Axonics Inc
NASDAQ:AXNX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
55.99
70.98
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Axonics Inc
Axonics Inc
PP&E Net
Axonics Inc
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Axonics Inc
NASDAQ:AXNX
|
PP&E Net
$41.6m
|
CAGR 3-Years
49%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
PP&E Net
$6.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
PP&E Net
$3.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
PP&E Net
$3.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
14%
|
|
|
|
Abbott Laboratories
NYSE:ABT
|
PP&E Net
$10.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
6%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
PP&E Net
$4.4B
|
CAGR 3-Years
37%
|
CAGR 5-Years
30%
|
CAGR 10-Years
29%
|
|
Axonics Inc
Glance View
Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 517 full-time employees. The company went IPO on 2018-10-31. The company is engaged in developing and commercializing products for patients with bladder and bowel dysfunction. The bladder and bowel dysfunction includes implantable sacral neuromodulation (SNM) systems to treat urinary urge incontinence (UUI) and urinary urgency frequency (UUF), together referred to as overactive bladder (OAB), as well as fecal incontinence (FI), and non-obstructive urinary retention (UR), and a urethral bulking agent to treat female stress urinary incontinence (SUI). The company has designed and developed the rechargeable sacral neuromodulation (SNM) system (r-SNM System), which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company has two relating to its r-SNM System, a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. The company offers urethral bulking agent, Bulkamid for stress urinary incontinence.
See Also
What is Axonics Inc's PP&E Net?
PP&E Net
41.6m
USD
Based on the financial report for Sep 30, 2024, Axonics Inc's PP&E Net amounts to 41.6m USD.
What is Axonics Inc's PP&E Net growth rate?
PP&E Net CAGR 5Y
42%
Over the last year, the PP&E Net growth was 433%. The average annual PP&E Net growth rates for Axonics Inc have been 49% over the past three years , 42% over the past five years .
You don't have any saved screeners yet
